Brought to you by 
Lilly comes out on top with $70/share ImClone bid
08 Oct 2008
Executive Summary
Trumping a $62 per share bid first launched by Bristol-Myers Squibb in July, Eli Lilly has now agreed to acquire targeted cancer care company ImClone Systems for $70 per share (a 53% premium to ImClone's market average ten days prior to the initial Bristol announcement). The deal value for all of ImClone's 87mm outstanding shares and additional vested stock options is estimated at about $6.5bn. As of September 30, 2008, ImClone reported about $890mm in cash and cash equivalents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly comes out on top with $70/share ImClone bid
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice